SAB Biotherapeutics, Inc. announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company?s Board of Directors. Dr. Skyler?s career in diabetes spans more than five decades, and he is currently a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, Florida, where he served as Director of that Division from 2000 to 2004. From 1993 until 2015, he was Chairman of the NIH (NIDDK)-sponsored Diabetes Prevention Trial - Type 1 (DPT-1) and its successor Type 1 Diabetes TrialNet, a nationwide (and global) network conducting clinical trials to interdict type 1 diabetes.

He is Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute, University of Miami, where he previously was Area Leader for Immunomodulation and Tolerance. He also is a Member of the University of Miami Interdisciplinary Stem Cell Institute. A native of Philadelphia, Dr. Skyler is a graduate of Pennsylvania State University and Jefferson Medical College, and did his postgraduate training in Internal Medicine and in Endocrinology & Metabolism at Duke University Medical Center.